 |
 |
Therapeutic Cloning Treats Parkinson's Disease In Mice July 20, 2009 Research led by investigators at Statue Sloan-Kettering Cancer Center (MSKCC) has shown that salutary cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to expound on Parkinson's disease in mice. The study's results are published in the Procession 23 online number of the minutes Nature Drug. For the principal term, researchers showed that health-giving cloning or SCNT has been successfully used to study disease in the selfsame subjects from whom the endorse cells were derived. While this current business is in animals, it could have future implications as this method may be an effective habit to reduce transplant rejection and heighten recapture in other diseases and in other organ systems. In therapeutic cloning or SCNT, the focus of a somatic cell from a donor subject is inserted into an egg from which the heart has been removed. This cell then develops into a blastocyst from which embryonic stem cells can be harvested and differentiated for corrective purposes. As the genetic dirt in the resulting staunch cells comes from the donor subject, healthy cloning or SCNT would yield obedient to-unique to cells that are spared by the invulnerable system after transplantation. The late study shows that therapeutic cloning can take up Parkinson's disease in a mouse follow. The scientists used skin cells from the tail of the creature to fashion customized or autologous dopamine neurons the missing neurons in Parkinson's disease. The mice that received neurons derived from one at a time matched stem cell lines exhibited neurological recovery. But when these neurons were grafted into mice that did not genetically match the transplanted cells, the cells did not survive well and the mice did not recover. The work was led by higher- ranking author Lorenz Studer, MD, Head of the Shoot Stall and Tumor Biology Laboratory within the Sloan-Kettering Begin at MSKCC, and get up to author Viviane Tabar, MD, Neurosurgeon and control room scientist at MSKCC. The work was performed in collaboration with scientists at the Riken Alliance in Kobe, Japan. Other MSKCC researchers who contributed to this study are: Mark Tomishima, Georgia Panagiotakos, George Al-Shamy, Bill Chan, and Jayanthi Menon. Scientists in Japan include group leader Teruhiko Wakayama and scientists Eiji Mizutani, Sayaka Wakayama and Hiroshi Ohta. This research was supported by the US National Institute of Neurological Disorders and Strike, the Starr Tri-institutional Stem Chamber Initiative, the Michael J. Fox Foundation seeking Parkinson's Research, the Michael W. McCarthy Fundamental principle and an unrestricted grant from the Kinetics Understructure. Memorial Sloan Kettering Cancer Center 1275 York Ave. Unfledged York, NY 10021 Common States http://www.mskcc.org Rayilyn Brown Director AZNPF Arizona Chapter National Parkinson Foundation [log in to unmask] ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn